Drugs and patents in ATC class A05AX - Other drugs for bile therapy

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
LIVMARLI	maralixibat chloride
BYLVAY	odevixibat
LIVDELZI	seladelpar lysine
>Tradename	>Generic Name

Last updated: June 5, 2026

Executive summary: ATC A05AX is a small, heterogeneous class where market dynamics are driven more by product-specific regulatory status and country-by-country exclusivity than by a single dominant active ingredient. Patent risk is similarly fragmented: many products sit behind composition and method-of-use patents, while others rely on short-duration formulation/processing protections. The generic entry profile for A05AX products is therefore mostly determined at the molecule and dosage-form level via Orange Book (US), national registers (EU), and company-specific litigation over secondary patents (formulations, manufacturing, and clinical-method claims).

What drugs are in ATC A05AX “Other drugs for bile therapy,” and who sells them?

Direct answer: A05AX is defined as “other drugs for bile therapy” and includes bile-related actives that do not fit into the main bile acid or choleretic subclasses. Coverage varies by geography because national listings do not always map 1:1 to the ATC code. Market share is concentrated in the brands and generics for each active ingredient, not across the class.

Key actives typically found in A05AX (by product, not code)

Common examples in bile-therapy adjacent portfolios include:

Ursodeoxycholic acid (UDCA) derivatives where specific products are categorized outside main bile acid codes in some jurisdictions.
Bile acid sequestration / bile binding products that are not classified under the dominant ATC bile acid subclasses in all systems.
Bile flow and cholestasis adjuncts positioned under “other” in certain classification mappings.
Novel bile-therapy agents in smaller geographies that can shift between subclasses when ATC reclassifications occur.

Business implication: Treat A05AX as an aggregation bucket. Patent and exclusivity analysis must be done molecule-by-molecule because the code does not predict claim scope or expiration timing.

Which patents protect bile therapy products in A05AX? Composition, formulation, and method-of-use

Direct answer: For most A05AX bile-therapy products, the patent estate that blocks generics is usually split across:

Composition-of-matter (active ingredient or salts/solvates),
Pharmaceutical composition (formulation, excipient system, dosage form, particle engineering), and
Methods (indications such as cholestasis, bile flow improvement, pruritus relief, or disease-specific protocols).

Patent clusters that matter in A05AX disputes

Formulation patents: controlled release, improved bioavailability, microencapsulation, dissolution profile changes, or bile-specific delivery strategies.
Manufacturing/process patents: crystallization conditions, drying parameters, milling, polymorph control.
Method-of-use patents: clinical endpoint-driven claims tied to cholestasis management, bilirubin improvement, itching reduction, or response rates in defined patient populations.
Second medical use claims: common in Europe via Swiss-type claims and related claim formats.

How A05AX estates differ from “mainstream” bile acids

Where UDCA is present, estates often include:

Known composition claims that have expired or are expiring, while
New formulation and indication patents extend market life,
Manufacturing IP limits generic manufacturing equivalence even when composition claims are weak.

Where the product is less established, the opposite pattern can appear: strong composition IP plus fewer, narrower formulation patents.

When do A05AX products lose exclusivity in the US and EU? A practical exclusivity timeline model

Direct answer: A05AX products lose exclusivity on three different clocks:

Patent expiration (composition, formulation, method-of-use),
Regulatory exclusivity (US: Hatch-Waxman exclusivity and exclusivity associated with 505(b)(1) or new clinical studies; EU: data exclusivity and market protection depending on authorization type),
New-use patenting and pediatric/extension strategies that can push practical entry dates.

US: What to track for A05AX

Orange Book listing and exclusivity codes linked to NDAs/505(b)(1)s.
Method-of-use patents listed in the Orange Book that can support Paragraph IV actions.
Delisting patterns: when sponsors drop patents that are not defendable, generics gain faster entry.

EU: What to track for A05AX

SPC (Supplementary Protection Certificates) tied to the basic patent.
National patent lifetimes and enforcement jurisdictions.
Data/market protection under the centralized vs national authorization route.
Post-authorization variations that sometimes create new patented formulations.

Business implication: In A05AX, the “last patent standing” often is not the primary drug substance patent. It is usually a formulation or method-of-use listed late in the product lifecycle.

What paragraph IV challenges exist for A05AX bile therapy drugs, and what are the common settlement patterns?

Direct answer: For A05AX, Paragraph IV challenges are sporadic and product-specific. When they occur, they often target:

formulation patents (BE bioequivalence arguments),
method-of-use patents (carve-outs or label design),
manufacturing/process claims (hard to design around without changing process).

Settlement patterns seen in bile-therapy classes

“Design-around” labeling settlements: generic enters with a narrower indication aligned to non-infringing label.
Trigger-based entry: generic entry tied to patent expiry, not to “end of litigation.”
At-risk launch offsets: less common in heavily formulation-locked products, more common where method patents are weak or delisted.

Business implication: For A05AX, settlement risk is driven by whether the sponsor can preserve enforceable secondary patents through claim amendments and venue selection, and whether the generic can accept label restrictions.

What is the Orange Book status of A05AX bile therapy drugs (patents listed, expirations, and exclusivity codes)?

Direct answer: The Orange Book status must be assessed per NDA/505(b)(1) product. A05AX code assignment is not sufficient to identify which US products are listed with which patent families.

Orange Book items that drive generic launch feasibility

Dosage form/strength-specific patents: formulation patents often list by strength.
Method-of-use patents: determine whether the generic must omit certain indications.
Expired or expiring patents: the number of active listed patents correlates with settlement likelihood and litigation burden.
Exclusivity codes: can block generic approval even if patent challenges are filed.

Business implication: A05AX market timing in the US is a “listing count” problem: the more listed patents that are both relevant and not delisted, the higher the friction.

How many patents cover A05AX bile therapy products, and how strong is the estate?

Direct answer: A05AX estates usually have fewer total families than blockbuster bile-therapy products, but a higher share of enforceable secondary IP (formulation/manufacturing/method). Strength is best measured by:

number of Orange Book-listed patents still in force,
overlap across composition, formulation, and method families,
litigation history (repeated defenses or claim narrowing).

Patent strength heuristics for A05AX

Weak sign: composition patents expired; remaining patents are narrow formulation claims that can be designed around by particle/dissolution engineering.
Strong sign: remaining patents cover core clinical method-of-use with endpoints and are harder to carve out from labeling.

Business implication: For investment and licensing, the “defensibility map” matters more than the total patent count.

Which A05AX products face biosimilar or biologic-like risks?

Direct answer: Biosimilar risk is not a typical issue for A05AX bile-therapy products because the class is predominantly small-molecule and non-biologic. The practical risk is instead “generic drug” risk: formulation and indication carve-outs.

How does A05AX compare with ATC A05AA and other bile-related classes on patent and market dynamics?

Direct answer: Compared with dominant bile acid subclasses, A05AX generally:

has more heterogeneous assets and fewer repeatable product templates,
exhibits more product-specific patent strategies (formulation extension and indication layering),
has fewer opportunities for a single generic player to attack multiple products with a shared platform.

Competitive dynamic differences

Mainstream bile acid brands: often have established composition families and more predictable expiration profiles.
A05AX “other bile therapy”: often uses incremental improvements and method-of-use patenting, producing irregular entry timing.

Business implication: Cross-class comparisons can mislead unless mapped to the exact active ingredient, route of administration, and labeled indications.

Which companies are likely challenging A05AX bile therapy patents, and what are the typical entry strategies?

Direct answer: In A05AX, challenger activity tends to come from:

large generic manufacturers filing ANDAs for oral solid dosage forms where BE is feasible,
specialty generics that focus on formulation design-around,
authorized generics where patent risk is high and settlement is cheaper than litigation.

Typical entry strategies by patent type

If method patents dominate: challengers pursue label carve-outs and narrower indication language.
If formulation patents dominate: challengers replicate dissolution and bioavailability while attempting to avoid infringing features (particle size, excipients, release mechanism).
If process patents dominate: challengers change manufacturing route, which can introduce cost and supply risks.

What formulations are protected in A05AX bile therapy (IR vs ER, particles, salts/solvates)?

Direct answer: Protected formulation themes are usually:

controlled-release or delayed-release systems for bile-relevant delivery,
improved dissolution targets tied to clinical performance,
polymorph/salt/solvate engineering where relevant,
excipient and granulation control that affects bioavailability and stability.

Practical impact on generic development

controlled-release patents often require sophisticated formulation and risk failure in similarity testing,
polymorph/process patents make it difficult to source directly without a license if the sponsor’s IP covers the manufacturing route.

What patent litigation affects market entry for bile therapy drugs in A05AX?

Direct answer: Litigation risk is product-specific and tends to cluster around:

Orange Book-listed method-of-use patents in US,
SPC validity and secondary patent enforceability in EU,
claim construction battles over formulation/process features.

Business implication: For A05AX, litigation outcomes can rapidly reshape market timing via delisting, partial invalidation, or enforceability determinations.

Key market-entry scenarios for A05AX: at-risk launch vs settlement vs delayed entry

Direct answer: Generic entry scenarios follow predictable risk tiers:

Clean entry: limited active secondary patents; fast label alignment.
Settlement-driven entry: method patents in force; generic accepts carve-outs.
Delayed entry: formulation/process patents strong; litigation or redesign required.
High-friction: multiple overlapping enforceable patents across composition, formulation, and method; settlement becomes the dominant path.

What drives the scenario in A05AX

number of active listed patents at filing time,
sponsor’s willingness to enforce secondary patents,
generic’s formulation flexibility,
regulatory pathway (ANDA vs 505(b)(2)/505(b)(1) for reformulations).

Key Takeaways

A05AX is not a unified patent block. Patent risk and exclusivity are determined per active ingredient and per product label, not by the ATC code.
Secondary IP drives most entry friction. In A05AX, formulation and method-of-use patents often outlive basic substance IP.
Orange Book and SPC status are the gating variables. Generic entry timing tracks the last defendable listed patent and any regulatory exclusivity.
Litigation is sporadic but high impact. When challenged, A05AX outcomes often hinge on carve-outs and enforceability of secondary claims.
For market planning, use an estate map not a class map. Build timelines and enforcement layers at the molecule-strength-dosage-form level.

FAQs

What is the fastest pathway to generic approval for A05AX bile therapy products with method-of-use patents?
How do controlled-release and delayed-release formulation patents typically change ANDA bioequivalence risk in bile therapy?
What SPC and patent-term-extension strategies most commonly delay entry in bile-related small molecules in the EU?
When sponsors delist Orange Book patents in bile therapy, what does that imply for litigation survival and launch timing?
How do label carve-outs affect revenue protection for bile therapy brands under Paragraph IV settlements?

References

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (accessed 2026-06-05).
European Medicines Agency (EMA). Supplementary Protection Certificates (SPC) and patent-related regulatory protection overview. (accessed 2026-06-05).
US FDA. Hatch-Waxman Regulatory Exclusivity Guidance and related exclusivity provisions. (accessed 2026-06-05).
WHO Collaborating Centre for Drug Statistics Methodology. ATC Classification. (accessed 2026-06-05).

Drugs in ATC Class A05AX

Drugs in ATC Class: A05AX - Other drugs for bile therapy

Market Dynamics and Patent Landscape for ATC Class A05AX (Other Drugs for Bile Therapy): Exclusivity, Generics, and Litigation Risk